Navigation Links
Nanosyn, Inc. and PCAS Announce the Signing of a Joint-Venture Agreement to Operate PCAS-NANOSYN, LLC
Date:8/12/2009

LONGJUMEAU, PARIS and MENLO PARK, Calif., Aug. 12 /PRNewswire/ -- PCAS, a worldwide leader in commercial scale pharmaceutical synthesis and fine and specialty chemical manufacturing, and Nanosyn, a leading US based pharmaceutical contract research provider of preclinical chemistry and biology services, announce the signing of a joint-venture agreement to operate PCAS-NANOSYN, LLC, a Good Manufacturing Practice (cGMP) kilolab in Santa Rosa, Northern California.

The newly created company, PCAS-NANOSYN, LLC, will enable PCAS and Nanosyn to satisfy a broader range of customer needs in the pharmaceutical and biotech marketplaces by offering fully integrated custom chemical services from discovery to commercialization.

"The formation of this JV with such a reputable partner as we have found in Nanosyn allows us to place critical preclinical and clinical trial API synthetic capabilities nearer to our clients in the US," said Christian Moretti, Chairman of PCAS, "It is an ideal next step in our strategy to continue growing our customer base in North America and builds on the success of our PCAS America marketing office in New Jersey."

The joint venture operation will provide services out of an FDA inspected facility in Santa Rosa, California, housing six (GMP) suites, two of which are certified as Class 10,000 clean rooms. PCAS-NANOSYN, LLC customers will further benefit from the significant chemical and analytical resources within the parent companies, and the ability to seamlessly transfer projects for larger scale to PCAS' network of four FDA inspected pilot and commercial scale plants in Europe.

"We are excited to offer this suite of cGMP solutions as a result of this partnership. For our clients, this is a natural extension of Nanosyn's highly successful discovery services into process development, scale-up, and supply of preclinical and cGMP clinical trial quantities of APIs," said Nikolai Sepetov, President and CEO of Nanosyn, Inc. "Ensuring quality, start to finish, is fundamental to the success we share with our clients."

Currently, the PCAS-NANOSYN, LLC facility is fully operational and is founded on the assets of Seres Laboratories. Nanosyn acquired the physical assets of Seres in March of 2009 and retained its experienced staff in order to take advantage of its 30 year history as an FDA registered cGMP site. As part of PCAS-NANOSYN, LLC strategy to be the premier provider of high quality and cost efficient services for the pharmaceutical and biotechnology industries, the joint venture plans to expand the site by upgrading its existing R&D and analytical capabilities, while adding new, advanced capacities. Olga Issakova, Ph.D., Executive Vice President of Nanosyn, Inc., will serve as CEO of the newly formed company.

About Nanosyn:

Nanosyn (www.nanosyn.com) is a Contract Research Organization providing integrated drug discovery services, medicinal chemistry, made-to-order focused compound libraries, hit-to-lead optimization, assay development, screening and profiling services, process chemistry, and other innovative solutions to meet our partners' drug discovery needs. Founded in 1998, Nanosyn is privately held and self-funding. The company is headquartered in Menlo Park, California with sites in San Diego, California and Research Triangle Park, North Carolina.

About PCAS:

PCAS (www.pcas.com) is a listed group on the Paris Stockmarket. A leading Fine Chemical company, PCAS operates eight chemical plants in Europe and North America and offers world-class services related to the process development and manufacturing of multi-step, complex organic chemicals from kilolab to multi-ton scale. PCAS provides services for the pharmaceutical, flavor and fragrance, cosmetic, and industrial market sectors.


'/>"/>
SOURCE PCAS-NANOSYN, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Neurobiological Technologies Announces Termination of its License and Cooperation Agreement with Merz and Childrens Medical Center
2. Cryo-Cell Announces Strategic Partnership With S-Evans Biosciences, Inc.
3. WuXi PharmaTech Announces Second-Quarter 2009 Results
4. ValGenesis, Inc. Announces Integration of ValGenesis Solution with Microsoft SharePoint Server
5. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2009 Results
6. Advanced Life Sciences Announces Second Quarter 2009 Financial Results and Financial Outlook
7. Microfluidics International Corporation Announces Second Quarter 2009 Financial Results
8. Tolerx Announces Amendment to Phase 3 DEFEND Protocol
9. American Oriental Bioengineering Announces Change in Independent Auditor
10. Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery
11. Angiotechs Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver(R) PTX(R) Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... May 24, 2017 , ... ... for the Mid-Atlantic chapter of the Healthcare Businesswomen’s Association (HBA). Nominated ... HBA Mid-Atlantic chapter board meets in person once each quarter and holds monthly ...
(Date:5/24/2017)... 2017 As Ebola resurfaces in the ... 20 suspected cases now reported, a new analysis of the ... a correlation between the 2014 and 2017 outbreaks of the ... in 2012-13, which preceded the 2014 outbreak. An analysis of ... Replikin counts in 2014-15, which again precedes the current outbreak ...
(Date:5/23/2017)... ... May 22, 2017 , ... NetDimensions has been ranked ... Research Globe™ for Corporate Learning, 2017. , Aragon Research defines Leaders as organizations ... effectively perform against those strategies. NetDimensions’ ranking as a Leader due to its ...
(Date:5/23/2017)... ... ... Bacterial biofilms, surface adherent communities of bacteria that are encased in a ... and catheter infections to gum disease and the rejection of medical implants. Though ... year, there is currently a paucity of means for preventing their formation or treating ...
Breaking Biology Technology:
(Date:3/30/2017)... March 30, 2017  On April 6-7, 2017, Sequencing.com ... Genome hackathon at Microsoft,s headquarters in ... will focus on developing health and wellness apps that ... Hack the Genome is the first hackathon for ... world,s largest companies in the genomics, tech and health ...
(Date:3/27/2017)... March 27, 2017  Catholic Health Services (CHS) ... Systems Society (HIMSS) Analytics for achieving Stage 6 ... sm . In addition, CHS previously earned a ... using an electronic medical record (EMR). ... level of EMR usage in an outpatient setting.  ...
(Date:3/22/2017)... Lithuania , March 21, 2017   ... and object recognition technologies, today announced the release ... kit (SDK), which provides improved facial recognition using ... cameras on a single computer. The new version ... to improve accuracy, and it utilizes a Graphing ...
Breaking Biology News(10 mins):